![](https://www.techmonitor.ai/wp-content/uploads/sites/29/2024/01/ShortenthePathFromDiscoverytoApprovalofNovelTherapiesWPcover.jpg)
Shorten the Path From Discovery to Approval of Novel Therapies
By MedidataThe competitive race to develop and launch new therapies faces challenges, including lengthy timelines, increased costs, and low drug approval rates despite rising R&D spending. Organizations can leverage external evidence, such as real-world data (RWD), to improve outcomes. However, RWD may introduce biases and lack specificity.
Medidata Trial Design offers access to extensive clinical trial data from over 30,000 trials and 9 million patients, paired with advanced analytics and industry expertise. This enables clinical development teams to enhance trial planning, increase regulatory success probabilities, accelerate market entry, reduce risks, and minimize patient burden.
Download to find out more.
![](https://www.techmonitor.ai/wp-content/uploads/sites/29/2024/01/ShortenthePathFromDiscoverytoApprovalofNovelTherapiesWPcover.jpg)